Clinical Trial: Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06827080) titled 'Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer' on Feb. 10.

Brief Summary: 161Tb-NYM032 is a radiopharmaceutical labeled with a PSMA ligand, used for the treatment of metastatic castration-resistant prostate cancer, which is needed for clinical trial to be conducted.

Study Start Date: Feb. 11

Study Type: INTERVENTIONAL

Condition: Metastatic Castration-resistant Prostate Cancer, MCRPC Cancer

Intervention: DRUG: 30 mCi NYMO32

The initial dose is set at 30 mCi.

DRUG: 50 mCi NYMO32

The dose will be escalated to 50 mCi.

DRUG: 80 mCi NY...